| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
MagForce AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.002 |
| 52 Week High | €0.0098 |
| 52 Week Low | €0.0002 |
| Beta | 0 |
| 1 Month Change | 25.00% |
| 3 Month Change | -66.67% |
| 1 Year Change | -9.09% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -68.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| MF6 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.6% | 1.2% |
| 1Y | -9.1% | -8.3% | 2.0% |
Return vs Industry: MF6 matched the German Medical Equipment industry which returned -8.3% over the past year.
Return vs Market: MF6 underperformed the German Market which returned 2% over the past year.
Price Volatility
| MF6 volatility | |
|---|---|
| MF6 Average Weekly Movement | 44.6% |
| Medical Equipment Industry Average Movement | 4.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: MF6's share price has been volatile over the past 3 months.
Volatility Over Time: MF6's weekly volatility has decreased from 98% to 45% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | n/a | Ben Lipps | www.magforce.de/ |
MagForce AG develops advanced nanomedicine for cancer therapies. It offers NanoTherm therapy system, a combination of medical devices for the treatment of solid brain tumors; NanoPlan, a software that stimulates the temperature distribution in the treatment area; NanoTherm, a magnetic ferrofluid; and NanoActivator, a magnetic field generator. MagForce AG was founded in 1997 and is headquartered in Berlin, Germany.
MagForce AG Fundamentals Summary
| MF6 fundamental statistics | |
|---|---|
| Market cap | €61.15k |
| Earnings (TTM) | -€10.57m |
| Revenue (TTM) | €1.08m |
0.0x
P/S Ratio0.0x
P/E RatioIs MF6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MF6 income statement (TTM) | |
|---|---|
| Revenue | €1.08m |
| Cost of Revenue | €918.75k |
| Gross Profit | €158.39k |
| Other Expenses | €10.73m |
| Earnings | -€10.57m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did MF6 perform over the long term?
See historical performance and comparison